Spiro Sakiris - Oct 4, 2023 Form 4 Insider Report for INTELLIGENT BIO SOLUTIONS INC. (INBS)

Role
Chief Financial Officer
Signature
/s/ Spiro Sakiris
Stock symbol
INBS
Transactions as of
Oct 4, 2023
Transactions value $
$0
Form type
4
Date filed
10/6/2023, 06:43 PM
Previous filing
Jul 11, 2023
Next filing
Mar 21, 2024
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INBS Common Stock Purchase +113K +2398.45% 117K Oct 4, 2023 Held by Anest Holdings Pty Ltd F1, F4
holding INBS Common Stock 3.77K Oct 4, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INBS Common Stock Warrants (Series E) Purchase +113K 113K Oct 4, 2023 Common Stock 113K Held by Anest Holdings Pty Ltd F1, F2, F4
transaction INBS Common Stock Warrants (Series F) Purchase +113K 113K Oct 4, 2023 Common Stock 113K Held by Anest Holdings Pty Ltd F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are included within 112,727 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").
F2 The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.
F3 The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).
F4 These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.